A wider policy debate is emerging as demand for GLP-1 medicines increases.
According to guidance published by the Medicines and Healthcare products Regulatory Agency (MHRA), these drugs are classified as prescription-only to ensure proper clinical assessment and discussion of potential benefits and risks.
The agency has also issued warnings about counterfeit products, urging the public not to purchase weight-loss injections from private or online sellers.
Shifting public perception
Clinicians report that social media has reshaped expectations around GLP-1 therapies.
Also read: New review suggests nitrous oxide may reshape approaches to treatment-resistant depression
Several doctors note that platforms often present them as fast-acting slimming tools, a portrayal they say oversimplifies medical reality and contributes to supply pressure.
The MHRA states that GLP-1 therapy is intended for people with type 2 diabetes or for individuals who are overweight accompanied by related health problems.
NHS clinicians emphasise that these medicines should be part of a structured care plan, not a cosmetic shortcut.
Decisions, they say, must balance expected benefits with the patient’s broader health profile.
Also read: Researchers uncover early bone-health signals hidden in standard tests
Known risks and special precautions
The MHRA lists gastrointestinal discomfort as the most common side effect and notes that more serious complications can occur, though rarely.
Both the MHRA and NHS advise against use during pregnancy and breastfeeding and recommend specific discontinuation periods before attempting pregnancy.
As stock levels fluctuate, some pharmacists prioritise supplies for diabetes patients, raising questions about equitable access.
Public-health experts also warn that focusing too heavily on medication risks narrowing the wider conversation about obesity, which is shaped by social and environmental factors as much as individual physiology.
Also read: Man suffers stroke after consuming multiple energy drinks
Sources: GOV.UK, MHRA, and NHS.
Also read: The symptom patterns emerging in England’s H3N2 outbreak